View of THE PREVALENCE OF ADVERSE EVENTS FOLLOWING IMMUNIZATION OF THE 2ND DOSE OF VERO CELL (SINOPHARM) COVID-19 VACCINE AMONG PEOPLE VACCINATED AT THE VACCINATION SITE OF HANOI MEDICAL UNIVERSITY AND SOME RELATED FACTORS, 2021-2022

Return to Article Details THE PREVALENCE OF ADVERSE EVENTS FOLLOWING IMMUNIZATION OF THE 2ND DOSE OF VERO CELL (SINOPHARM) COVID-19 VACCINE AMONG PEOPLE VACCINATED AT THE VACCINATION SITE OF HANOI MEDICAL UNIVERSITY AND SOME RELATED FACTORS, 2021-2022 Download Download PDF